This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital Nephrotic Syndrome, Membranous Glomerulonephritis막성 사구체신염 선천성 신증후군 (막성사구체신염 선천성신증후군)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: N04.2 (congenital nephrotic syndrome with diffuse membranous glomerulonephritis) | Special Copayment Reduction: V263 (rare disease)
B. SynonymsCongenital nephrotic syndrome with diffuse membranous glomerulonephritis
C. Adult onsetLikelihood of first onset in adulthood very low — by the congenital nephrotic syndrome classification, onset is within 3 months to 1 year after birth, and most causes (infectious, immune-mediated) produce clear symptoms in the neonatal period or early infancy. First presentation after an asymptomatic course into adulthood is extremely exceptional.
1. History1957: Jones described membranous nephropathy → congenital syphilis, TORCH infections, and hereditary causes identified as causes of congenital/infantile membranous nephrotic syndrome → PLA2R1 antibody (2009) identified as the major antigen in adult idiopathic membranous nephropathy
2. CausesCongenital membranous nephrotic syndrome mostly has infectious (congenital syphilis, CMV, toxoplasma, rubella) or immune-mediated (neonatal lupus, maternal antibody transfer) mechanisms; rarely hereditary causes
3. GeneticsMostly no congenital nephrotic syndrome-specific gene variants; NPHS1 and NPHS2 variants reported in some; the PLA2R1 and THSD7A antigen-antibody mechanisms of adult idiopathic membranous disease play a different role in congenital disease
4. General epidemiologyCongenital membranous nephrotic syndrome is a minority among all congenital nephrotic syndromes; the association with congenital syphilis was historically important but has decreased since antibiotic treatment
5. PathophysiologyInfectious: immune complex deposition (subepithelial in the GBM) → complement activation → podocyte injury → membrane thickening; immune-mediated: transfer of maternal antibodies (anti-Ro, anti-DNA) → deposition within the GBM or subepithelially
6. SymptomsMassive proteinuria, edema, hypoalbuminemia; fever, hepatosplenomegaly, and jaundice possible with infectious causes; hematologic abnormalities with lupus association
7. SignsEdema; diffuse GBM thickening on light microscopy, spike formation on silver stain; granular IgG and C3 deposits on immunofluorescence; subepithelial deposits on electron microscopy
8. ScreeningMaternal infection tests (VDRL, TORCH); neonatal infection screening; maternal autoantibody tests (anti-Ro, anti-La, anti-dsDNA)
9. DiagnosisKidney biopsy (GBM thickening, subepithelial deposits); serum complement (consider infectious/lupus causes if C3, C4 low); TORCH tests; autoantibody panel
10. TreatmentTreatment of the cause first (antibiotics, antivirals); steroids/immunosuppressants (lupus-related); ACE inhibitors/ARBs; supportive care
11. PrognosisSpontaneous remission possible when the cause is removed (congenital syphilis, neonatal lupus); possible progression to ESRD with hereditary causes; overall slower progression than FSGS
12. PreventionPrevention of maternal infection (STD testing, TORCH prevention); control of maternal autoimmune disease; genetic counseling
13. References10 key references (with PMID or DOI)

1. History

Membranous glomerulonephritis (MGN) is one of the main causes of idiopathic nephrotic syndrome in adults; in 1957, Jones in the UK described the characteristic thickening of the glomerular basement membrane (GBM) and subepithelial deposits and classified it as an independent disease. It was later established that extensive (diffuse) membranous change of the glomeruli is characteristic, and the histologic diagnostic term 'diffuse membranous glomerulonephritis' has been used.

Congenital and infantile membranous glomerulonephritis differs fundamentally in pathogenic mechanism from adult idiopathic membranous nephropathy. Historically, congenital syphilis has long been recognized as an important cause of congenital membranous nephrotic syndrome. In the 1940s–60s, when syphilis was frequent, many cases were reported in which membranous changes were observed on kidney biopsy after syphilis infection was confirmed in infants with nephrotic syndrome presenting within weeks to months after birth. After penicillin treatment became widespread, the incidence of congenital syphilis-associated membranous nephrotic syndrome decreased markedly.

In the late 20th century, TORCH infections such as cytomegalovirus (CMV), toxoplasma, and hepatitis B virus were also reported as causes of congenital and infantile membranous glomerulonephritis. In addition, cases were described in neonatal lupus erythematosus (NLE) in which maternal anti-Ro/La antibodies cross the placenta, deposit in the kidney, and cause membranous or mixed glomerulonephritis. This established congenital membranous nephrotic syndrome as a heterogeneous group encompassing infectious, autoimmune, and rarely hereditary causes.

The M-type phospholipase A2 receptor (PLA2R1), the major antigen of adult idiopathic membranous nephropathy, was identified by Beck et al. in 2009, and additional antigens such as THSD7A, NELL-1, and SEMA3B were later discovered. However, this antigen-antibody mechanism is specific to adult idiopathic membranous disease and is distinct from the pathogenic mechanism of congenital and infantile membranous nephrotic syndrome. PLA2R1 antibody positivity has been reported only rarely in congenital membranous nephrotic syndrome.

2. Causes

Unlike adult idiopathic membranous nephropathy, congenital nephrotic syndrome with membranous glomerulonephritis mostly arises from infectious or immune-mediated mechanisms, and purely hereditary causes are rare.

Infectious causes: congenital syphilis (Treponema pallidum) was historically the most common cause of congenital membranous nephrotic syndrome. Treponemal antigens and antibodies against them form immune complexes that are deposited subepithelially in the GBM, activating complement and causing membrane thickening and podocyte injury. TORCH (Toxoplasma, Rubella, CMV, Herpes simplex) infections can also cause membranous nephrotic syndrome by the same immune complex mechanism, and CMV infection has been reported as a cause of membranous nephritis in infants. Membranous nephritis associated with hepatitis B surface antigen (HBsAg) is reported mainly in childhood, and congenital vertical transmission can also be a cause.

Immune-mediated causes: neonatal lupus (NLE) is a neonatal autoimmune disease that occurs when maternal anti-Ro52/Ro60 or anti-La antibodies cross the placenta to the fetus. Renal involvement in NLE is rare, but when it occurs it may show a membranous or mixed glomerulonephritis pattern. Lupus nephritis-like findings due to transfer of maternal anti-dsDNA antibodies have also been reported. In these cases, renal findings tend to improve with the spontaneous disappearance of maternal antibodies (3–6 months after birth).

Hereditary causes: cases have rarely been reported in which NPHS1 (nephrin) and NPHS2 (podocin) variants present as congenital nephrotic syndrome with a membranous pattern, but this is interpreted as the result of podocyte structural abnormalities, different from the pathogenic mechanism of typical membranous nephritis. LAMB2 (laminin β2) variants may also present in some cases as GBM abnormalities resembling membranous changes.

Idiopathic: classified as idiopathic when all of the above causes have been excluded, but true idiopathic membranous nephrotic syndrome is very rare in congenital onset. In this case, searching for unidentified gene variants with gene panel testing is recommended.

3. Genetics

Because congenital nephrotic syndrome with membranous glomerulonephritis is mostly not due to hereditary causes, discussion of modes of inheritance or specific gene variants is limited. However, when infectious or immune-mediated causes have been excluded, and especially when there is a family history, the possibility of hereditary glomerular disease should be evaluated systematically.

Among genes associated with congenital nephrotic syndrome, those related to the membranous pattern are summarized as follows. NPHS1 variants: cases have been reported in which initial histologic findings show membranous changes and then transition to an FSGS pattern as the disease progresses. LAMB2 variants: GBM thickening and electron microscopic abnormalities due to abnormal GBM constituent proteins may present as a membranous glomerulonephritis-like pattern. NPHS2 variants: in rare cases they present with a membranous pattern, but typically show FSGS or diffuse mesangial changes.

PLA2R1 gene polymorphisms (HLA-associated variants such as rs4664308, rs35771982), the main genetic background of adult idiopathic membranous nephropathy, are not directly related to congenital onset. In neonatal lupus, the maternal HLA-DR2 and HLA-DR3 genotypes associated with NLE are known to be related to maternal anti-Ro antibody production, but this is an effect of the maternal genotype, not the genotype of the fetus/newborn itself.

Therefore, when an infectious or immune-mediated cause is identified in congenital membranous nephrotic syndrome, genetic testing has low priority. However, when the cause is unknown, there is a family history, or other hereditary renal disease is possible, it is reasonable to perform a congenital nephrotic syndrome gene panel (including NPHS1, NPHS2, WT1, LAMB2, PLCE1).

4. General epidemiology

Accurate epidemiological data on the incidence of congenital nephrotic syndrome with membranous glomerulonephritis are limited. The membranous histologic type accounts for a minority of all congenital nephrotic syndromes, and its frequency differs by era (changes in the frequency of congenital syphilis) and region.

In the first half of the 20th century, when congenital syphilis was common, congenital syphilis-associated membranous nephrotic syndrome was reported relatively often, but after prenatal syphilis testing (VDRL/RPR) of pregnant women became universal and penicillin treatment became widespread, incidence due to this cause decreased markedly. However, syphilis incidence is still on the rise in some countries, so attention to congenital syphilis-associated nephrotic syndrome is needed. TORCH infections, especially congenital CMV infection, occur at a considerable frequency worldwide at about 0.3–1% per 1,000 births, and renal involvement develops in some of these.

Neonatal lupus (NLE) occurs at a frequency of about 1–2% in pregnancies in which the mother has an anti-Ro/La antibody-positive autoimmune disease (SLE, Sjögren syndrome), and renal involvement among these is even rarer. Worldwide, cases of renal involvement in NLE have been reported at the level of several hundred. There are no epidemiological data specific to congenital membranous nephrotic syndrome in Korea, but it is reported sporadically at pediatric nephrology centers and is registered and managed under Special Copayment Reduction code V263. Congenital onset is incomparably rarer than the incidence of adult idiopathic membranous nephropathy (about 10–12 per million adults).

5. Pathophysiology

The pathophysiology of congenital nephrotic syndrome with membranous glomerulonephritis differs by cause, but the common core is that immune complexes are deposited subepithelially in the GBM (between the podocytes and the GBM), activating complement and causing podocyte injury.

Infectious mechanism (congenital syphilis, etc.): pathogen antigens (treponemal antigens of Treponema pallidum, CMV proteins, etc.) circulate in the blood and form immune complexes with specific antibodies. Because of the high blood pressure and filtration pressure of the glomerular capillaries, these immune complexes pass through the GBM and are deposited subepithelially. The deposited immune complexes activate the complement pathway (C5b-9, membrane attack complex), causing podocyte injury, generation of reactive oxygen species, and release of proteolytic enzymes. As a result, podocytes secrete new GBM material that surrounds the deposits (this appears as 'spikes' on silver stain), eventually forming diffuse thickening of the GBM. When the causative infection is treated, new formation of immune complexes stops and existing deposits are gradually resorbed, so renal findings may improve.

Immune-mediated mechanism (neonatal lupus): maternal IgG antibodies (anti-Ro, anti-La, anti-dsDNA) cross the placenta into the fetal circulation. These antibodies bind to glomerular antigens in the neonatal kidney or form circulating immune complexes that are deposited within the GBM or subepithelially. Complement activation and podocyte injury by the deposited immune complexes cause membranous or mixed glomerulonephritis. In neonatal lupus, maternal antibodies disappear spontaneously within 3–6 months after birth, so renal involvement also tends to improve spontaneously over this period.

6. Symptoms

The clinical symptoms of congenital nephrotic syndrome with membranous glomerulonephritis present as a combination of renal and systemic symptoms depending on the underlying cause.

Renal symptoms: the main symptoms are the four cardinal findings of nephrotic syndrome: massive proteinuria, hypoalbuminemia, edema, and hyperlipidemia. Within a few weeks to 3 months after birth, generalized edema (starting with eyelid edema and spreading to the whole body), ascites, and pleural effusion appear. Hematuria may be more common than in minimal change disease but is often less prominent than in FSGS. Blood pressure is initially normal or low (decreased intravascular volume due to hypoalbuminemia), but hypertension may develop with progression.

Systemic symptoms of infectious causes: in congenital syphilis, in addition to renal symptoms, systemic findings such as rash (petechiae or copper-colored spots), snuffles, osteochondritis, hepatosplenomegaly, jaundice, and pancytopenia accompany the disease. CMV infection may be accompanied by jaundice, hepatosplenomegaly, microcephaly, periventricular calcifications, thrombocytopenia, and hearing loss. Toxoplasmosis presents with hydrocephalus, chorioretinitis, periventricular calcifications, and jaundice.

Symptoms of immune-mediated causes (neonatal lupus): facial erythematous rash (photosensitive), congenital atrioventricular block (bradycardia from complete heart block), cytopenias (hemolytic anemia, thrombocytopenia, leukopenia), liver function abnormalities, and renal involvement (rarely) appear. Congenital atrioventricular block is an irreversible complication and may require permanent pacemaker implantation.

7. Signs

Physical examination: generalized edema (eyelids, limbs, abdomen), ascites (shifting dullness, fluid wave), pleural effusion (decreased breath sounds, dullness to percussion). In congenital syphilis, snuffles, skin rash (including palms and soles), hepatosplenomegaly, jaundice, and low body weight are observed. In CMV infection, microcephaly, jaundice, hepatosplenomegaly, and petechiae (thrombocytopenia) are characteristic. In neonatal lupus, facial erythematous rash and bradycardia (atrioventricular block) are characteristic.

Laboratory findings: urine proteinuria (4+), possible microscopic hematuria. Low serum albumin, hyperlipidemia. C3 and C4 complement: may be low with infectious causes (congenital syphilis, congenital hepatitis B) or lupus association; normal in idiopathic membranous disease. Serum VDRL/RPR and TPHA (syphilis tests). TORCH tests (IgM antibodies: CMV, toxoplasma, rubella). Maternal and neonatal anti-Ro, anti-La, and anti-dsDNA antibodies (evaluation of lupus association). HBsAg, HBV DNA (to exclude hepatitis B-associated membranous disease).

Kidney biopsy findings: light microscopy: diffuse thickening of the GBM, with mild or no mesangial proliferation. Silver stain (Jones methenamine silver): 'spike' formation around subepithelial GBM deposits. Immunofluorescence: granular deposits of IgG and C3 along the GBM (fine granular pattern). PLA2R immunostaining is positive in adult idiopathic membranous disease but usually negative in congenital onset. Electron microscopy: subepithelial electron-dense deposits in the GBM, foot process effacement, and GBM thickening are characteristic.

8. Screening

Screening for congenital membranous nephrotic syndrome consists mainly of maternal screening for causative factors (infection, autoimmunity) and neonatal testing based on clinical suspicion.

Maternal prenatal infection screening: the prenatal test package performed in all pregnant women (VDRL/RPR syphilis tests, hepatitis B surface antigen, HIV, rubella antibodies, urine CMV, etc.) is the basis for prevention and early detection of congenital infection-associated nephrotic syndrome. In particular, syphilis testing (VDRL/RPR) is performed in Korea in early pregnancy and in the third trimester, and if positive, immediate penicillin treatment prevents vertical transmission.

Monitoring of mothers with autoimmune disease: when anti-Ro/La antibody positivity is confirmed in pregnant women with SLE or Sjögren syndrome, fetal heart rate monitoring (early detection of complete atrioventricular block) is performed, and urine protein monitoring after birth is performed with the possibility of lupus-related renal involvement in the newborn in mind.

Testing based on clinical suspicion in newborns: when edema and proteinuria presenting within a few weeks to 3 months after birth are accompanied by infectious or autoimmune findings such as jaundice, hepatosplenomegaly, skin rash, or microcephaly, a TORCH test panel and syphilis tests are performed immediately. If proteinuria persists even after infectious causes are excluded, the diagnosis is confirmed with kidney biopsy and gene panel testing.

9. Diagnosis

The diagnosis of congenital nephrotic syndrome with membranous glomerulonephritis is made in three steps: fulfilling the clinical criteria for nephrotic syndrome, tests for infectious/immune-mediated causes, and kidney biopsy.

Tests for the cause: serum VDRL/RPR and TPHA (confirmation of syphilis), TORCH IgM and IgG antibodies (CMV, toxoplasma, rubella, HSV), measurement of maternal and neonatal anti-Ro52/Ro60, anti-La, and anti-dsDNA antibodies, HBsAg, HBV DNA, HCV RNA (hepatitis B and C). Measurement of complement (C3, C4, CH50) evaluates for immune complex-mediated disease (infectious, lupus-associated). Measurement of serum PLA2R1 antibodies (to exclude adult-type idiopathic membranous disease) is usually negative in congenital onset but can be performed.

Kidney biopsy: kidney biopsy is performed when the diagnosis is unclear from clinical findings and tests for the cause alone. The combination of diffuse GBM thickening on light microscopy, spike formation on Jones silver stain, granular IgG and C3 deposits on immunofluorescence, and subepithelial deposits on electron microscopy is the confirmatory criterion for membranous glomerulonephritis. Pink deposits (immune deposits) are identified on Masson trichrome stain. Immunohistochemical staining for pathogen antigens (syphilis, CMV) in tissue helps identify the cause.

Genetic testing: when infectious and immune-mediated causes have all been excluded or there is a family history, a congenital nephrotic syndrome gene panel is performed. The panel should include at least NPHS1, NPHS2, WT1, LAMB2, and PLCE1.

10. Treatment

Treatment of congenital nephrotic syndrome with membranous glomerulonephritis depends on the cause, and treatment of the cause takes top priority.

Treatment of infectious causes: when congenital syphilis is confirmed, penicillin G (crystalline aqueous penicillin G, 50,000 units/kg/dose IV q12h for 7 days, then q8h for 3 days, total 10 days) or intramuscular benzyl penicillin G is the standard treatment. After treatment, proteinuria and renal findings improve within a few months. In CMV-associated nephrotic syndrome, antiviral treatment with ganciclovir is considered, but its direct effect on renal involvement is limited. In hepatitis B-associated membranous nephritis, steroid use is judged carefully along with antiviral treatment such as lamivudine or entecavir.

Treatment of immune-mediated causes (neonatal lupus): in neonatal lupus, most symptoms (rash, cytopenias, liver function abnormalities) improve spontaneously with the spontaneous disappearance of maternal antibodies (3–6 months after birth). When renal involvement is severe, short-term steroid (prednisolone) treatment is considered. Complete atrioventricular block does not recover spontaneously, so permanent pacemaker implantation is required.

Conservative treatment: ACE inhibitors/ARBs reduce proteinuria and control intraglomerular pressure. Severe edema is controlled with intravenous albumin and diuretics. Infection prevention (prophylactic antibiotics, vaccines), thrombosis prevention, and nutritional support are provided concurrently. Steroids and immunosuppressants (cyclophosphamide, MMF) are used cautiously when the cause has been identified, and when idiopathic membranous nephrotic syndrome has not been excluded, the decision is made after a period of observation.

Kidney transplantation: kidney transplantation is considered when the disease progresses to ESRD despite treatment of the cause and conservative treatment. Post-transplant recurrence of membranous nephrotic syndrome is rare when there is no hereditary cause. Complete treatment of the causative infection or confirmation of disappearance of immune complexes before transplantation is recommended.

11. Prognosis

The prognosis of congenital nephrotic syndrome with membranous glomerulonephritis varies greatly with the underlying cause and the timing of treatment. When the cause can be removed (congenital syphilis, neonatal lupus), spontaneous improvement or complete remission after treatment is possible, and the prognosis is good.

Congenital syphilis-associated: with early and appropriate penicillin treatment, renal findings often improve within a few months, reaching complete remission. Long-term damage to renal function is rare, and resolution of proteinuria and normalization of serum albumin are expected after treatment.

Neonatal lupus-associated: maternal antibodies disappear spontaneously within 3–6 months after birth, and renal involvement also mostly improves spontaneously along with this. Permanent residual renal impairment is rare. However, complete atrioventricular block is irreversible, so long-term cardiac follow-up is required. The future risk of developing SLE is slightly higher than in the general population, but the absolute risk is low.

Idiopathic or hereditary causes: when no cause is identified or there is a hereditary cause, progression to ESRD is frequent. Overall, progression has been reported to be slower than in FSGS, but individual variation is large. The degree of interstitial fibrosis and tubular atrophy on biopsy helps predict long-term prognosis.

12. Prevention

Prevention of congenital nephrotic syndrome with membranous glomerulonephritis focuses mainly on prevention and early treatment of the causative infections and autoimmune diseases.

Infection prevention: performing prenatal syphilis testing (VDRL/RPR) in early pregnancy and in the third trimester and completing immediate penicillin treatment if positive can prevent more than 90% of vertical transmission of congenital syphilis. To prevent CMV infection, pregnant women are advised on personal hygiene (handwashing) and minimizing contact with the urine and saliva of infants and children. CMV vaccine development is under way for pregnant women at high risk for CMV (seronegative). Completion of hepatitis B vaccination and immediate administration of immunoglobulin and vaccine to newborns of HBsAg-positive mothers prevent vertical transmission.

Monitoring of autoimmune disease: in pregnant women positive for anti-Ro/La antibodies (SLE, Sjögren), fetal heart rate monitoring (weeks 18–26 of pregnancy, weekly or every other week) detects complete atrioventricular block early, and dexamethasone administration is considered if needed. Studies indicate that appropriate medication adjustment to minimize lupus disease activity during pregnancy (hydroxychloroquine, low-dose aspirin, etc.) helps prevent NLE.

Genetic counseling: when hereditary membranous nephrotic syndrome with a family history is suspected, genetic counseling and prenatal/preimplantation genetic testing are offered.


13. References

  1. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21. DOI: 10.1056/NEJMoa0810457. PMID: 19571279.
  2. Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int. 2017;91(3):566-574. DOI: 10.1016/j.kint.2016.09.048. PMID: 28126256.
  3. Jalanko H. Congenital nephrotic syndrome. Pediatr Nephrol. 2009;24(11):2121-2128. DOI: 10.1007/s00467-007-0633-9. PMID: 17968594.
  4. Bonilla-Felix M, Parra C, Dajani T, et al. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int. 1999;55(5):1885-1890. DOI: 10.1046/j.1523-1755.1999.00431.x. PMID: 10231454.
  5. Wisuthsarewong W, Soongswang J, Chantorn R. Neonatal lupus erythematosus: clinical character, investigation, and outcome. Pediatr Dermatol. 2011;28(2):115-121. DOI: 10.1111/j.1525-1470.2011.01340.x. PMID: 21477213.
  6. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481-490. DOI: 10.1136/jcp.56.7.481. PMID: 12835292.
  7. Congenital Syphilis — United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(12):317-322. DOI: 10.15585/mmwr.mm6912a1. PMID: 32214085.
  8. Suzuki J, Takahashi K, Ito K, et al. Clinical characteristics of pediatric membranous nephropathy in Japan. Pediatr Nephrol. 2022;37(2):365-372. DOI: 10.1007/s00467-021-05194-6. PMID: 34302547.
  9. Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529-1561. DOI: 10.1007/s00467-020-04519-1. PMID: 32382828.
  10. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis — a new look at an old entity. N Engl J Med. 2012;366(12):1119-1131. DOI: 10.1056/NEJMra1108178. PMID: 22435371.